Mini-dose glucagon is effective at diabetes camp

Hasan, Khalid; Kabbani, Mahmoud; Christensen, R.

doi:10.1016/j.jpeds.2004.03.027

Cited by 10 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14 A 7-day camp for 220 children in Arizona reported 28 episodes of severe hypoglycaemia including two seizures, requiring seven doses of glucagon and one intravenous glucose infusion. 15 Another 7-day camp reported one seizure and one unresponsive episode of hypoglycaemia in 45 campers. 16 Clearly a trade-off is required between safety and ideal BGL levels.…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of blood glucose management practices at a diabetes camp

Gunasekera

Ambler

2006

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of blood glucose management practices at a diabetes camp

Gunasekera

Ambler

2006

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

“…Camp Conrad-Chinnock (Angelus Oaks, CA) is located at 6,800-feet altitude. The altitude, exercise, and dietary changes impact on glucose control, and severe, nocturnal hypoglycemia is a well-recognized complication at camps (11). The camp setting allows a number of studies to be conducted simultaneously with local remote monitoring and also allows testing of controller in a rugged, real-world setting.…”

Section: Introductionmentioning

confidence: 99%

Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp

et al. 2014

View full text Add to dashboard Cite

OBJECTIVETo determine the safety and efficacy of an automated unified safety system (USS) in providing overnight closed-loop (OCL) control in children and adolescents with type 1 diabetes attending diabetes summer camps.RESEARCH DESIGN AND METHODSThe Diabetes Assistant (DIAS) USS used the Dexcom G4 Platinum glucose sensor (Dexcom) and t:slim insulin pump (Tandem Diabetes Care). An initial inpatient study was completed for 12 participants to evaluate safety. For the main camp study, 20 participants with type 1 diabetes were randomized to either OCL or sensor-augmented therapy (control conditions) per night over the course of a 5- to 6-day diabetes camp.RESULTSSubjects completed 54 OCL nights and 52 control nights. On an intention-to-treat basis, with glucose data analyzed regardless of system status, the median percent time in range, from 70–150 mg/dL, was 62% (29, 87) for OCL nights versus 55% (25, 80) for sensor-augmented pump therapy (P = 0.233). A per-protocol analysis allowed for assessment of algorithm performance. The median percent time in range, from 70–150 mg/dL, was 73% (50, 89) for OCL nights (n = 41) versus 52% (24, 83) for control conditions (n = 39) (P = 0.037). There was less time spent in the hypoglycemic range <50, <60, and <70 mg/dL during OCL compared with the control period (P = 0.019, P = 0.009, and P = 0.023, respectively).CONCLUSIONSThe DIAS USS algorithm is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting.

show abstract

“…Whilst participants are studied in a ‘real-world’ surroundings, monitoring by medical and research personnel allows interventions to take place in case of safety concerns or system malfunctions to underpin safety aspects. Hypoglycemia is a well-recognized complication at diabetes camps often attributed to increased exercise and dietary alterations [56]. Thus, camp settings provide a challenge testbed for closed-loop systems.…”

Section: Glucose Responsive Suspension Of Insulin Deliverymentioning

confidence: 99%

Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes

Tauschmann

Hovorka

2017

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction: Nocturnal glucose control remains challenging in children and adolescents with type 1 diabetes due to highly variable overnight insulin requirements. The issue may be addressed by glucose responsive insulin delivery based on real-time continuous glucose measurements.Areas covered: This review outlines recent developments of glucose responsive insulin delivery systems from a paediatric perspective. We cover threshold-based suspend application, predictive low glucose suspend, and more advanced single hormone and dual-hormone closed-loop systems. Approaches are evaluated in relation to nocturnal glucose control particularly during outpatient randomised controlled trials.Expert opinion: Significant progress translating research from controlled clinical centre settings to free-living unsupervised home studies have been achieved over the past decade. Nocturnal glycaemic control can be improved whilst reducing the risk of hypoglycaemia with closed-loop systems. Following the US regulatory approval of the first hybrid closed-loop system in non-paediatric population, large multinational closed-loop clinical trials and pivotal studies including paediatric populations are underway or in preparation to facilitate the use of closed-loop systems in clinical practice.

show abstract

Mini-dose glucagon is effective at diabetes camp

Cited by 10 publications

References 6 publications

Safety and efficacy of blood glucose management practices at a diabetes camp

Safety and efficacy of blood glucose management practices at a diabetes camp

Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp

Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes

Contact Info

Product

Resources

About